Bio-Path (NASDAQ:BPTH) Now Covered by Analysts at began coverage on shares of Bio-Path (NASDAQ:BPTHFree Report) in a research note released on Wednesday. The firm issued a sell rating on the stock.

Bio-Path Trading Up 1.5 %

Bio-Path stock opened at $0.41 on Wednesday. The stock has a market cap of $4.70 million, a P/E ratio of -0.19 and a beta of 1.36. The stock has a 50 day moving average of $0.68 and a 200-day moving average of $1.25. Bio-Path has a 52 week low of $0.35 and a 52 week high of $3.85.

Bio-Path (NASDAQ:BPTHGet Free Report) last released its earnings results on Tuesday, August 15th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.52) by ($0.01). During the same quarter in the prior year, the firm posted ($0.42) earnings per share. As a group, equities analysts predict that Bio-Path will post -1.7 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Bio-Path

Several institutional investors and hedge funds have recently made changes to their positions in the company. Citadel Advisors LLC acquired a new stake in shares of Bio-Path during the 3rd quarter valued at approximately $35,000. Renaissance Technologies LLC acquired a new stake in shares of Bio-Path during the 2nd quarter valued at approximately $70,000. Finally, Virtu Financial LLC acquired a new stake in shares of Bio-Path during the 1st quarter valued at approximately $38,000. 5.74% of the stock is owned by institutional investors and hedge funds.

About Bio-Path

(Get Free Report)

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.

Featured Stories

Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with's FREE daily email newsletter.